Memory Functioning and Antidepressant Treatment
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00296933|
Recruitment Status : Completed
First Posted : February 27, 2006
Last Update Posted : February 17, 2009
|Condition or disease||Intervention/treatment||Phase|
|Depression Major Depressive Disorder||Drug: Escitalopram Drug: Bupropion XL||Phase 3|
Purpose of the Present Study:
The purpose of the present study is to comprehensively evaluate memory functioning of MDD patients before and after 8 weeks of antidepressant treatment with bupropion-XL or escitalopram. A neuropsychological test battery will incorporate multiple aspects of memory functioning including: short-term & working memory; verbal, non-verbal, spatial and prospective memory.
Major Research Questions:
- Which subtypes of memory at baseline are more impaired?
- What is the relationship between memory impairment and symptom severity and previous number of episodes or duration of illness?
- Is successful AD treatment associated with improvement in memory functioning?
- Is there a main effect by AD type?
- On which subtypes of memory do patients improve, worsen, or remain neutral in the 2 different AD groups? (Main effect of memory type?)
- What is the relationship between change in memory function and symptomatic outcome?
This is a randomized, double-blind, double-dummy trial comparing the memory functioning of depressed subjects before and after 8 weeks of treatment with bupropion-XL as compared to escitalopram.
All consenting, eligible subjects will receive either active bupropion-XL or active escitalopram following the baseline visit. Doses will be fixed with an opportunity for dose reduction if subjects are unable to tolerate fixed dose.
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||60 participants|
|Intervention Model:||Parallel Assignment|
|Official Title:||Memory Functioning and Antidepressant Treatment: A Randomized Controlled Trial Comparing Escitalopram and Bupropion XL|
|Study Start Date :||December 2005|
- General Verbal Memory-California Verbal Learning Test® -2nd ed (CVLT® -II)
- Hamilton Rating Scale for Depression - 17-Item
- Clinical Global Impression Severity and Improvement Ratings
- Short Term & Working Memory: Wechsler Memory Scales III
- Nonverbal Memory - Faces
- WMS III Logical Memory (Prose Recall)
- Nonverbal Memory - Spatial Memory
- Shipley Institute of Living Scale
- Prospective Memory
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00296933
|University Health Network|
|Toronto, Ontario, Canada, M5G 2C4|
|Principal Investigator:||Sidney H Kennedy, MD||University Health Network, Toronto|